Table 2 AFT and OR estimates for the adjusted model with log-normal random effects

Mepolizumab (75 mg)

1.60 (1.19, 2.16) *

0.97 (0.83, 1.13)

1.25 (0.65, 2.39)

2.11 (0.90, 4.92)

Mepolizumab (100 mg)

1.38 (0.99, 1.92)

0.95 (0.82, 1.09)

1.66 (0.70, 3.94)

1.59 (0.62, 4.05)

Mepolizumab (250 mg)

2.18 (1.44, 3.29) *

0.94 (0.76, 1.16)

1.14 (0.40, 3.27)

2.62 (0.95, 7.18)

Mepolizumab (750 mg)

2.02 (1.38, 2.96) *

0.85 (0.72, 1.00) *

1.30 (0.53, 3.17)

1.42 (0.47, 4.33)

Age (in decades)

1.09 (0.98, 1.22)

1.02 (0.97, 1.08)

0.79 (0.63, 1.00) *

1.00 (0.78, 1.28)

Female

1.08 (0.86, 1.36)

1.05 (0.93, 1.18)

1.20 (0.65, 2.23)

0.37 (0.19, 0.73) *

FEV1 (liter)

0.81 (0.40, 1.66)

1.11 (0.77, 1.59)

0.89 (0.19, 4.26)

6.22 (0.90, 43.1)

Nasal polyp

1.15 (0.83, 1.60)

1.00 (0.85, 1.19)

0.94 (0.37, 2.36)

1.27 (0.51, 3.15)

ACQ score

0.90 (0.80, 1.00)

1.01 (0.96, 1.06)

0.97 (0.71, 1.33)

0.70 (0.52, 0.95) *

BMI

1.07 (0.89, 1.28)

1.14 (1.04, 1.26) *

1.94 (1.26, 3.00) *

0.63 (0.33, 1.19)

FEV1 reversibility (percentage)

1.27 (0.86, 1.89)

0.90 (0.74, 1.09)

0.94 (0.38, 2.34)

0.26 (0.04, 1.85)

Baseline eosinophil

0.77 (0.55, 1.08)

1.08 (0.95, 1.24)

2.01 (0.53, 7.67)

1.49 (0.79, 2.83)

History of smoking

1.13 (0.87, 1.46)

0.96 (0.85, 1.08)

1.31 (0.69, 2.48)

0.47 (0.19, 1.13)

Duration of asthma (in decades)

0.98 (0.90, 1.06)

1.03 (0.99, 1.07)

1.08 (0.85, 1.37)

1.00 (0.80, 1.26)

Baseline SCS daily dose

0.96 (0.88, 1.05)

1.08 (1.03, 1.14) *

1.32 (1.06, 1.65) *

0.18 (0.04, 0.92) *

Black/Hispanic v. White

0.76 (0.55, 1.06)

0.85 (0.72, 1.00) *

4.93 (2.39, 10.17) *

1.30 (0.42, 4.00)

Baseline IgE

1.04 (0.95, 1.15)

0.96 (0.91, 1.02)

1.02 (0.75, 1.37)

0.64 (0.34, 1.22)

No. of exacerbations year prior to study

0.47 (0.34, 0.64) *

0.73 (0.63, 0.86) *

1.65 (0.87, 3.16)

0.33 (0.07, 1.44)

\(N^{\ddagger }\)

1.10 (1.02, 1.19) *

1.04 (1.00, 1.08) *

1.20 (1.00, 1.43)

-

\(N_S^{\ddagger }\)

0.73 (0.58, 0.93) *

0.99 (0.89, 1.10)

-

-